Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (ListingObligations and Disclosure Requirements) Regulations, 2015, we enclose herewith theproceedings of the 26th AGM of the Company held today i.e. on Friday, 8th August, 2025.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt held its 26th AGM on 8th August 2025 via video conferencing, chaired by Founder Chairman Dr. Habil Khorakiwala, attended by 159 members and all directors including the CFO and auditors. Key items put to shareholders included adoption of FY25 audited financial statements, re-appointment of Dr. Murtaza Khorakiwala (retiring by rotation), appointment of Mr. Virendra G. Bhatt as Secretarial Auditor for 5 years, and approval of material related party transactions. Two special resolutions seek to raise the remuneration of Executive Director Dr. Huzaifa Khorakiwala and Managing Director Dr. Murtaza Khorakiwala from ₹2.80 Cr to ₹4 Cr per annum (capped at ₹6 Cr), and to authorise a capital raise of up to ₹2,000 Crore via QIP or public/private offerings. The Chairman highlighted FY25 total income of ₹3,074 crore, EBITDA of ₹418 crore, 78% revenue from international markets, and a net debt-to-equity ratio of 0.27. Nobel Peace Laureate Prof. Mohan Munasinghe was announced as the company's new ESG Advisor, with sharper focus on biosimilars and diabetes care. Voting results will be filed with stock exchanges in due course.
The proposed ₹2,000 Crore capital raise (via QIP) is the most material item for shareholders, as it could lead to equity dilution once executed. Higher promoter-family remuneration (potentially up to ₹6 Cr each) is a governance item minority shareholders may scrutinise, while solid FY25 financials and a low debt-to-equity ratio provide comfort.